Когнитивные нарушения у больных сахарным диабетом и артериальной гипертензией в практике амбулаторного врача

1. Богданов А.Р., Богданов Р.Р., Мазо В.К., Феофанова Т.Б. Когнитивные нарушения при дисциркуляторной энцефалопатии и ожирении. Cons. Med. 2013; 15 (2): 46–51.
2. Захаров В.В. Всероссийская программа исследований эпидемиологии и терапии когнитивных расстройств в пожилом возрасте («Прометей»). Неврол. журн. 2006; 11: 27–32.
3. Захаров В.В. Современные подходы к терапии когнитивных нарушений, не достигающих выраженности деменции. Эффективная фармакотерапия. 2013; 1: 56–60.
4. Касаткин Д.С. Нейроваскулярная единица как точка приложения действия некоторых вазоактивных препаратов. Журн. неврол. и психиатр. им. С.С.Корсакова, 2012; с. 9.
5. Касаткин Д.С. Полимодальность эффектов препарата кавинтон: экспериментальные и клинические доказательства. Журн. неврол. и психиатр. им. С.С.Корсакова. 2010; 9 (2): 8–12.
6. Левин О.С., Ильясова Ф.Н. Когнитивные нарушения при сахарном диабете типа 2. Cons. Med. 2012; 14 (9).
7. Левин О.С. Умеренное когнитивное расстройство: возможности диагностики и лечения. Справочник поликлинического врача. 2012; 2.
8. Табеева Г.Р., Азимова Ю.Э. Мультимодальная стратегия нейропротекции при инсульте: результаты российской многоцентровой клинико-эпидемиологической программы «сокол» (Сравнительная Оценка эффективности Кавинтона и Общепринятых схем Лечения пациентов, перенесших острое нарушение мозгового кровообращения). Журн. неврол. и психиатр. им. С.С.Корсакова. 2012; 12 (2): 37–47.
9. Чуканова Е.И. Эффективность кавинтона в лечении пациентов 
с хронической недостаточностью мозгового кровообращения. Российская многоцентровая клинико-эпидемиологическая программа «КАЛИПСО». Журн. неврол. и психиатр. им. С.С.Корсакова. 2010; 110 (12): 49.
10. Шишкова В.Н., Осыченко М.Е. Проблема когнитивного дефицита у пациентов с метаболическим синдромом. Cons. Med. 2011; 13 (10): 114–8.
11. Areosa SA, Grimley EV. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev 2002; 4: CD003804. 
12. Arvanitakis Z, Schneider JA, Wilson RS et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006; 67: 1960–5.
13. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63: 582–92.
14. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathologica 2009; 118 (1): 103–13.
15. Biessels GJ, Staekenborg S, Brunner E et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64–74.
16. Birns J, Kalra L. Cognitive function and hypertension. J Hum Hypertens 2009; 23: 86–96. 
17. Brown WR, Thore CR. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol Appl Neurobiol 2011, 37 (1): 56–74.
18. Busse A, Hensel A, Guhne U et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006; 67: 2176–85.
19. Chen CCV, Chen YC, Hsiao HY et al. Neurovascular abnormalities in brain disorders: highlights with angiogenesis and magnetic resonance imaging studies. J Biomed Science 2013; 20: 47.
20. Cherbuin N et al. Risk factors of transition from normal cognition to mild cognitive disorder: the PATH through Life Study. Dement Geriatr Cogn Disord 2009; 28: 47–55.
21. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169–78.
22. Etgen T, Bickel H, Förstl H. Metabolic and endocrine factors in mild cognitive impairment. Ageing Res Rev 2010; 9: 280–8.
23. Etgen T, Sander D, Bickel H, Förstl H. Mild Cognitive Impairment and Dementia: The Importance of Modifiable Risk Factors. Dtsch Arztebl Int 2011; 108 (44): 743–50.
24. Ferri CP, Prince M, Brayne C et al. Alzheimer’s Disease International: Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–7.
25. Group HPSC: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
26. Gurol ME, Irizarry MC, Smith EE et al. Plasma {beta}-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006; 66: 23–9. 
27. Leveille SG, Penninx BWJH, Melzer D et al. Sex differences in the prevalence of mobility disability in old age: the dynamics of incidence, recovery and mortality. J Gerontol Psychol Sci Soc Sci 2000; 55B: 41–50.
28. Luchsinger JA, Reitz C, Patel B et al. Relation of Diabetes to Mild Cognitive Impairment. Arch Neurol 2007; 64: 570–5. 
29. Luchsinger JA. Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis 2012; 30 (0): 185–98.
30. Lucka T, Luppaa M, Briela S, Riedel-Hellera SG. Incidence of Mild Cognitive Impairment: A Systematic Review. Dement Geriatr Cogn Disord 2010; 29: 164–75.
31. Manschot SM, Brands AMA, van der Grond J et al. On behalf of the Utrecht Diabetic Encephalopathy Study G. Brain Magnetic Resonance Imaging Correlates of Impaired Cognition in Patients With Type 2 Diabetes. Diabetes 2006; 55: 1106–13.
32. Manton KG, Corder LS, Stallard E. Estimates of change in chronic disability and institutional incidence and prevalence rates in the US elderly population from the 1982, 1984, and 1989 National Long Term Care Survey. J Gerontol 1993; 48: 153–66. 
33. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009; 2: CD003160.
34. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289:76–9.
35. Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat Rev Cardiol 2010; 7 (12): 686–98.
36. Park CR. Cognitive effects of insulin in the central nervous system. Neurosci Biobehav Rev 2001; 25: 311–23.
37. Petersen RC, Knopman DS. MCI is a clinically useful concept. Int Psychogeriatr 2006; 18: 394–402.
38. Qiu C, Winblad B, Fratiglioni L. Low diastolic pressure and risk of dementia in very old people: a longitudinal study. Dement Geriatr Cogn Disord 2009; 28: 213–9. 
39. Ramos-Estebanez C, Moral-Arce I, Gonzales-Mandly A et al. Vascular cognitive impairment in small vessel disease: clinical and neuropsychological features of lacunar state and Binswanger’s disease. Age and Ageing 2011; 40: 175–80.
40. Roberts RO, Geda YE, Knopman DS et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 2008; 65: 1066–73.
41. Sabia S, Elbaz A, Dugravot A et al. Impact of Smoking on Cognitive Decline in Early Old Age. The Whitehall II Cohort Study. Arch Gen Psychiatry 2012; 69 (6): 627–35.
42. Sagare A, Deane R, Bell RD et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007; 13: 1029–31. 
43. Scarmeas N, Stern Y, Mayeux R et al. Mediterranean diet and mild cognitive impairment. Arch Neurol 2009; 66: 216–25.
44. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197–204.
45. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360: 1623–30.
46. Slinin Y, Paudel ML, Taylor BC et al. 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology 2010; 74: 33–41.
47. Sofi F, Valecchi D, Bacci D et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med 2010; 269: 107–17.
48. Stewart R et al. Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 2009; 54: 233–40.
49. Tas Ü, Verhagen AP, Bierma-Zeinstra SMA et al. Prognostic factors of disability in older people:  a systematic review. Br J General Practice 2007; April: 319–23.
50. van Uffelen JG, Chinapaw MJ, van Mechelen W, Hopman-Rock M. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. Br J Sports Med 2008; 42: 344–51.
51. Vermeer SE et al for the Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: The Rotterdam Scan Study. Stroke 2003; 34: 1126–9.
52. Vinyoles E, De la Figuera M, Gonzalez-Segura D. Cognitive function and blood pressure control in hypertensive patients over 60 years of age: 
COGNIPRES study. Curr Med Res Opin 2008; 24: 3331–9.
53. Wadley VG et al. Cognitive status, stroke symptom reports, and modifiable risk factors among individuals with no diagnosis of stroke or transient ischemic attack in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Stroke 2007; 38: 1143–7. 
54. Warren MF, Serby MJ, Roane DM. The effects of testosterone on cognition in elderly men: a review. CNS Spectr 2008; 13: 887–97.
55. Winblad B, Palmer K, Kivipelto M et al. Mild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240–6.
56. Wolf PA et al. Relation of obesity to cognitive function: importance of central obesity and synergistic influence of concomitant hypertension. The Framingham Heart Study. Curr Alzheimer Res. 2007; 4: 111–6.
57. Xu G, Liu X, Yin Q et al. Alcohol consumption and transition of mild cognitive impairment to dementia. Psychiatry Clin Neurosci 2009; 63 (1): 43–9.
58. Yafaffe K, Kanaya A, Lindquist K et al. The Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline. JAMA 2004; 292: 2237–42.
59. Yaffe K, Blackwell T, Whitmer RA et al. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 2006; 10: 293–5.
60. Yaffe K, Petersen RC, Lindquist K et al. Subtype of mild cognitive impairment and progression to dementia and death. Dement Geriatr Cogn Disord 2006; 22: 312–9.
61. Zhao L, Teter B, Morihara T et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J Neurosci 2004; 24: 11120–6.

Г.Р.Табеева

ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России